CLINICAL TRIALS PROFILE FOR DECASPRAY

All Clinical Trials for Decaspray

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00895245 ↗	Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy	Terminated	National Cancer Institute (NCI)	Phase 2	2009-02-01	RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck cancer undergoing chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying how well fosaprepitant dimeglumine together with palonosetron hydrochloride and dexamethasone works in preventing nausea and vomiting caused by cisplatin in patients with stage III or stage IV head and neck cancer undergoing chemotherapy and radiation therapy.
NCT00895245 ↗	Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy	Terminated	University of Washington	Phase 2	2009-02-01	RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck cancer undergoing chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying how well fosaprepitant dimeglumine together with palonosetron hydrochloride and dexamethasone works in preventing nausea and vomiting caused by cisplatin in patients with stage III or stage IV head and neck cancer undergoing chemotherapy and radiation therapy.
NCT01049945 ↗	Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	Completed	Mayo Clinic	Phase 1/Phase 2	2010-02-01	RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Giving bendamustine hydrochloride together with lenalidomide and dexamethasone may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of bendamustine hydrochloride and lenalidomide when given together with dexamethasone and to see how well they work in treating patients with relapsed multiple myeloma.
NCT01057225 ↗	Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma	Completed	Mayo Clinic	Phase 1/Phase 2	2010-03-01	RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by blocking blood flow to the tumor. Giving combination chemotherapy together with carfilzomib and thalidomide may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of carfilzomib when given together with cyclophosphamide, thalidomide, and dexamethasone in treating patients with newly diagnosed active multiple myeloma.
NCT01072773 ↗	Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis	Completed	Mayo Clinic	Phase 2	2010-03-01	RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib, cyclophosphamide, and dexamethasone together works in treating patients with primary systemic light chain amyloidosis.

Clinical Trial Conditions for Decaspray

Condition Name

Condition Name for Decaspray
Intervention	Trials
Refractory Multiple Myeloma	3
Multiple Myeloma	2
Stage III Squamous Cell Carcinoma of the Larynx	1
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity	1

Condition MeSH

Condition MeSH for Decaspray
Intervention	Trials
Neoplasms, Plasma Cell	5
Multiple Myeloma	5
Amyloidosis	1
Nasopharyngeal Neoplasms	1

Clinical Trial Locations for Decaspray

Trials by Country

Trials by Country for Decaspray
Location	Trials
United States	23

Trials by US State

Trials by US State for Decaspray
Location	Trials
Minnesota	5
Ohio	2
Arizona	2
Missouri	2
Florida	2

Clinical Trial Progress for Decaspray

Clinical Trial Phase

Clinical Trial Phase for Decaspray
Clinical Trial Phase	Trials
Phase 2	3
Phase 1/Phase 2	4

Clinical Trial Status

Clinical Trial Status for Decaspray
Clinical Trial Phase	Trials
Completed	5
Active, not recruiting	1
Terminated	1

Clinical Trial Sponsors for Decaspray

Sponsor Name

Sponsor Name for Decaspray
Sponsor	Trials
Mayo Clinic	4
National Cancer Institute (NCI)	3
University of Washington	1

Sponsor Type

Sponsor Type for Decaspray
Sponsor	Trials
Other	8
NIH	3
Industry	1